Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management cut its Supernus Pharmaceuticals stake by 86.2% in the second quarter, selling 457,443 shares and retaining 73,175 shares valued at approximately $3.4 million.
• Supernus shares opened at $47.87, up 2.1%, with a market capitalization of about $2.78 billion. The stock has traded between $41.01 and $59.68 over the past year.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $62.83, although ratings range from Strong Buy to Sell.

Assenagon Asset Management S.A. lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 86.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,175 shares of the specialty pharmaceutical company's stock after selling 457,443 shares during the period. Assenagon Asset Management S.A. owned about 0.13% of Supernus Pharmaceuticals worth $3,403,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Rockefeller Capital Management L.P. grew its holdings in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock valued at $42,000 after purchasing an additional 660 shares during the period. Torren Management LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $49,000. EverSource Wealth Advisors LLC acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $51,000. Hantz Financial Services Inc. lifted its position in shares of Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at approximately $55,000.

Supernus Pharmaceuticals Trading Up 2.1%

Supernus Pharmaceuticals stock opened at $47.87 on Thursday. The company has a 50-day moving average price of $46.35 and a 200 day moving average price of $48.88. Supernus Pharmaceuticals, Inc. has a 12-month low of $41.01 and a 12-month high of $59.68. The stock has a market cap of $2.78 billion, a P/E ratio of -24.93, a PEG ratio of 0.86 and a beta of 0.56.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several recent analyst reports. Zacks Research raised shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $62.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source